Sanofi, BioNTech cull mRNA clinical cytokine cancer candidate based on early data

Sanofi and BioNTech’s vision of using mRNA to prime anti-cancer immune attacks has failed to hold up to clinical scrutiny. After running an interim analysis of early-phase data, the partners have jointly decided to scrap development of the candidate as an intratumoral therapy.